Thiel Capital

Pioneering a biologically enhanced future for humanity.

Network Bio operates a clinical and molecular data library focused on facilitating precision medicine for common human diseases. Its platform serves as a centralized repository for clinical and molecular data, allowing researchers to analyze patterns and correlations. This analysis can lead to the development of new treatments and diagnostic tools, thereby advancing medical research and improving patient outcomes.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Rollup is a software company that offers a collaborative platform aimed at enhancing the development and optimization of complex hardware systems. Utilizing model-based systems engineering, the platform integrates engineering analysis, design, and documentation, facilitating seamless communication among teams. This approach allows users to streamline their processes, reducing reliance on costly tools and specialized software, while also minimizing the need for specially-trained engineers. By providing an efficient and economical solution, Rollup supports teams in building advanced hardware models and systems effectively.

Neros Technologies specializes in autonomous drone services aimed at enhancing defense capabilities. The company has developed a technology-based platform that focuses on keeping personnel off the battlefield, addressing vulnerabilities faced by dismounted soldiers in combat situations. By leveraging advanced drone technology, Neros Technologies seeks to provide innovative solutions that empower clients in the defense sector, helping to improve safety and operational effectiveness against armored threats.

Quantum system develops manufactures and sells unmanned aerial systems, which provide aerial intelligence to commercial and governmental clients around the world.

Heading Health is a technology-enabled mental health platform dedicated to enhancing access to affordable care. The company provides personalized treatment solutions that utilize evidence-based therapeutics and advanced technologies such as transcranial magnetic stimulation, telepsychiatry, and intramuscular ketamine. By leveraging these tools, Heading Health aims to deliver effective and convenient mental health services, helping patients achieve meaningful outcomes and improved well-being.

Generation Prime is a digital healthcare platform focused on women's healthcare services, particularly in vitro fertilization (IVF) treatments. The company aims to address various family planning and medical needs by offering a closed-loop system for IVF and related health services. Through the integration of technology, Generation Prime enables healthcare professionals to deliver these services more efficiently and at a lower cost, enhancing patient care and accessibility.

SPARK Neuro Inc. is a neuroscience company based in New York, founded in 2013. It specializes in market research for the advertising and entertainment industries, utilizing neuroscience tools to enhance audience engagement and storytelling. Additionally, SPARK Neuro focuses on analyzing brain activity to improve clinical care and therapeutic discovery. The company partners with prestigious institutions to develop its patented neural metrics and advanced machine learning algorithms, exemplified by the SPARK Scan, a 10-minute EEG-based evaluation that helps identify early signs of changes in brain health. Through its innovative platform, SPARK Neuro aims to make brain health measurement universally accessible, enabling healthcare professionals to better understand and address neurological and psychiatric conditions.

Ready.net is a software development company that specializes in creating business and operational tools for internet service providers (ISPs). Founded in 2020 and headquartered in San Francisco, California, the company offers a product called Back Office Secret Sauce (BOSS). This innovative software enables ISP subscribers to manage their networks independently, facilitating tasks such as upgrading service plans, selecting additional services, paying bills online, and receiving assistance through a chatbot. Ready.net aims to enhance the operational efficiency of local ISPs while providing a user-friendly experience for their customers.

Alloy Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2017. The company focuses on democratizing access to essential drug discovery platforms and services, primarily through its Alloy-Gx platform. This innovative platform features a royalty-free suite of immunocompetent transgenic mice that facilitate in vivo human antibody discovery. Alloy Therapeutics has developed humanized transgenic antibody discovery technology, which offers broad, non-exclusive access to drug discovery tools, allowing scientists to engage in their antibody projects more efficiently and effectively. The company's mission is to enhance the drug discovery process by providing accessible and advanced resources for researchers in the field.

Vienna is a smart canvas for ideas. It is a place to collect thoughts and everything that comes with photos, videos, code, music, files, and, of course, text. They serve services for creators, students, and teams to build and discover ideas.

Inflection Points operates a specialized employment and training platform focused on the bitcoin and cryptocurrency sectors. The company offers services that facilitate connections between employers and candidates, enabling businesses to recruit talent and individuals to discover job opportunities within the growing crypto industry. Additionally, Inflection Points provides training programs aimed at enhancing skills relevant to bitcoin and cryptocurrency, further supporting workforce development in this dynamic field.

Regent is a maritime mobility company focused on developing electric flying machines for coastal transportation. The company specializes in designing and manufacturing seagliders, which are wing-in-ground-effect crafts that operate a few meters above the water's surface. These innovative vehicles combine the high speed of an airplane with the low operating costs of a boat, enabling them to travel at speeds of up to 180 mph (290 km/h) over suitable ranges for regional trips. Regent's seagliders aim to replace traditional ferries and short-haul aircraft on coastal routes, providing fast, safe, and cost-effective transportation solutions that connect coastal cities and islands. By revolutionizing regional transportation, Regent seeks to enhance connectivity among coastal communities while promoting sustainable travel options.

Mynaric AG specializes in laser communication solutions for high data rate and long-distance wireless data transmission between moving objects. Founded in 2009 and headquartered in Gilching, Germany, the company develops a range of products including air-to-ground, air-to-air, and space terminals, as well as optical ground stations. These systems are essential for aerospace communication networks, enabling ultra-high data rates and secure connectivity for applications across terrestrial, airborne, and space environments. Mynaric operates in two primary segments: Air, which includes HAWK terminals, and Space, featuring CONDOR terminals. Its innovative technology supports a variety of applications such as satellite constellations and high-altitude networks, positioning the company at the forefront of the communication equipment sector. Additional locations in Los Angeles and Washington, D.C. expand its operational reach.

Ex-human specializes in developing a digital human platform that provides customizable interactive artificial intelligence characters. These AI characters are designed to facilitate engaging conversations through text, audio, images, and video, catering to diverse industries such as gaming, dating, chatbots, and influencer marketing. By offering hyper-realistic open-domain conversations, Ex-human enables businesses to enhance user engagement and create entertaining experiences for their audiences.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

Angiex is a biotechnology company focused on developing vascular-targeted biotherapeutics for cancer treatment. Founded by leading scientists, the company specializes in antibody-drug conjugate therapies that address key aspects of endothelial biology, particularly angiogenesis. Angiex's lead product utilizes a novel approach to deliver therapeutic agents directly to the nucleus of tumor cells and to the activated endothelium of tumors and inflamed vessels. This innovative method aims to enhance the efficacy of treatments for various solid tumors, including pancreatic, lung, liver cancers, and glioblastoma multiforme. With intellectual property originating from Beth Israel Deaconess Medical Center, Angiex operates out of LabCentral in Cambridge, positioning itself at the forefront of cancer therapeutics.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Voices is a live video streaming platform that allows creators to monetize their work through donations and subscriptions. Voices will assist content creators in making this a "stunning mass phenomenon," as well as "promote the growth of the creative economy's middle class."

Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to combat herpes simplex virus and its related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutic and prophylactic vaccine candidates that aim to reduce the transmission of the herpes virus and effectively manage symptoms associated with its reactivation. By harnessing rational engineering techniques, Rational Vaccines seeks to revolutionize the treatment, prevention, and diagnosis of herpes infections, ultimately improving the quality of life for those affected by these conditions.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Ready.net is a software development company that specializes in creating business and operational tools for internet service providers (ISPs). Founded in 2020 and headquartered in San Francisco, California, the company offers a product called Back Office Secret Sauce (BOSS). This innovative software enables ISP subscribers to manage their networks independently, facilitating tasks such as upgrading service plans, selecting additional services, paying bills online, and receiving assistance through a chatbot. Ready.net aims to enhance the operational efficiency of local ISPs while providing a user-friendly experience for their customers.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Advano, also known as NanoStar, Inc., is a New Orleans-based company that specializes in silicon nanotechnology, focusing on the development of advanced silicon anode materials for lithium-ion batteries. Founded in 2014 and a graduate of Y Combinator in 2017, Advano offers scalable solutions that enhance the energy density and longevity of lithium-ion batteries by integrating or replacing traditional graphite components. Its innovative products cater to various industries, including electric vehicles and consumer electronics, and are designed to improve energy storage and charging capabilities. By providing low-cost, high-performance materials, Advano aims to support the domestic battery supply chain and facilitate the transition to sustainable energy solutions.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

SPARK Neuro Inc. is a neuroscience company based in New York, founded in 2013. It specializes in market research for the advertising and entertainment industries, utilizing neuroscience tools to enhance audience engagement and storytelling. Additionally, SPARK Neuro focuses on analyzing brain activity to improve clinical care and therapeutic discovery. The company partners with prestigious institutions to develop its patented neural metrics and advanced machine learning algorithms, exemplified by the SPARK Scan, a 10-minute EEG-based evaluation that helps identify early signs of changes in brain health. Through its innovative platform, SPARK Neuro aims to make brain health measurement universally accessible, enabling healthcare professionals to better understand and address neurological and psychiatric conditions.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Terminal Inc., established in 2017 with headquarters in San Francisco and offices across North America and Mexico, specializes in talent solutions for technology companies. The company facilitates the recruitment, onboarding, and management of remote global engineering teams, enabling businesses to scale efficiently. Terminal offers global talent acquisition services, market insights, operational support including HR, benefits, payroll, and stock option administration, along with access to a connected tech community.

Invicta Medical is a medical technology company focused on developing innovative treatments for sleep apnea and snoring. Founded in 2013 and based in California, the company has created a wearable neurostimulation device that detects and treats disturbed breathing through electrical stimulation. This device aims to overcome the limitations of traditional therapies, which are often expensive, intrusive, and associated with low patient compliance rates. By providing a smart, comfortable, and cost-effective solution, Invicta Medical seeks to enhance the effectiveness of treatment for sleep disorders and improve patient outcomes.

ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.

3T Biosciences, Inc. is an immunotherapy company established in 2017 and based in Menlo Park, California. The company focuses on developing innovative treatments for cancer and other T-cell-mediated diseases by utilizing synthetic biology and machine learning technologies. Its approach involves discovering novel targets for drug development, which aims to enhance the effectiveness of cancer therapies. Through its research and development efforts, 3T Biosciences is committed to providing healthcare professionals with advanced treatment options for patients facing cancer-related illnesses.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Angiex is a biotechnology company focused on developing vascular-targeted biotherapeutics for cancer treatment. Founded by leading scientists, the company specializes in antibody-drug conjugate therapies that address key aspects of endothelial biology, particularly angiogenesis. Angiex's lead product utilizes a novel approach to deliver therapeutic agents directly to the nucleus of tumor cells and to the activated endothelium of tumors and inflamed vessels. This innovative method aims to enhance the efficacy of treatments for various solid tumors, including pancreatic, lung, liver cancers, and glioblastoma multiforme. With intellectual property originating from Beth Israel Deaconess Medical Center, Angiex operates out of LabCentral in Cambridge, positioning itself at the forefront of cancer therapeutics.

Invicta Medical is a medical technology company focused on developing innovative treatments for sleep apnea and snoring. Founded in 2013 and based in California, the company has created a wearable neurostimulation device that detects and treats disturbed breathing through electrical stimulation. This device aims to overcome the limitations of traditional therapies, which are often expensive, intrusive, and associated with low patient compliance rates. By providing a smart, comfortable, and cost-effective solution, Invicta Medical seeks to enhance the effectiveness of treatment for sleep disorders and improve patient outcomes.

Legendary Entertainment is a media company that specializes in creating and distributing content for television and digital platforms globally. The company engages in the development, co-production, co-financing, and distribution of motion pictures, collaborating with other production studios to enhance its offerings. Legendary Entertainment is dedicated to producing content that appeals to mainstream audiences, with a particular emphasis on the influential fandom demographic. Its portfolio includes box-office films, television shows, and comic storylines, reflecting a commitment to delivering engaging entertainment across various media formats.